From NuGOwiki
The NuGOwiki Metabolite Database is a joint initiative of NuGO and HMDB
| Taxonomy Navigation Box; search by |
|
All Metabolites | Biochemical | Nutritional | Functional | Metabolic Pathways | Diseases | Phenotypes | Physiological Processes | Protein |
| IL1ra | |
|---|---|
| [[Image:{{{Image}}}|thumb|220px|2D structure for IL1ra]] | |
| Chemical Name | |
| Chemical Formula | |
| CAS Number | |
| Chemical Information | |
| Biochemical Taxonomy | |
| Functional Taxonomy | |
| Nutritional Taxonomy | |
| Metabolic Pathways | |
| Biofluid Location | |
| Tissue Location | |
| Normal Biofluid Concentrations | |
| Normal Tissue Concentrations | |
| Diseases / Conditions Related to Nutrition | |
| Other (Monogenic Disorders) | |
| Abnormal Biofluid Concentrations | |
| Abnormal Tissue Concentrations | |
| Physiological Processes | |
| Authors: | L. Pellis |
| Affiliations: | TNO, the Netherlands |
Contents |
Introduction
IL-1 receptor antagonist (IL-1ra) is a member of the IL-1 family, which acts as a natural IL-1 inhibitor. The balance between IL-1 and IL-1ra plays an important role in the course of various inflammatory diseases, such as arthritis. IL-1ra is produced as different isoforms, one secreted (sIL-1ra) and three intracellular (icIL-1ra1, 2, 3), derived from the same gene. Human articular chondrocytes produce sIL-1ra in response to IL-1. This effect, which is enhanced by IL-6 and inhibited by dexamethasone, reflects increased transcription from the sIL-1ra promoter. The production of sIL-1ra by chondrocytes may have a protective effect against articular inflammatory and catabolic responses.
Biological Function
guidelines
Inhibits the activity of IL-1 by binding to its receptor.
Catabolism
Diseases / Conditions Related to Nutrition
Associated decreased protein/metabolite profile
Associated increased protein/metabolite profile
Other (Monogenic) Disorders
Nutritional Information
Drivers for biological variation